



ASX RELEASE
1 April 2016

Entitlement Offer – Dispatch of Information Booklet and Entitlement & Acceptance Form – Tissue Therapies Limited (trading as Factor Therapeutics Limited) (ASX Code: TIS)

Tissue Therapies Limited ACN 101 955 088 trading as Factor Therapeutics (ASX:TIS) (**Factor**) would like to advise that the non-renounceable Entitlement Offer Information Booklet and Entitlement & Acceptance Form announced on 18 March 2016 will be despatched to eligible shareholders today.

For more information:

Shareholders can contact Factor's share registry on 1800 990 479 (within Australia) or +61 1800 990 479 (outside Australia) between 8.30am and 5.30pm (Sydney time) Monday to Friday.

Corporate Contact

Dr. Christian P. Behrenbruch
Executive Director
Tissue Therapies Limited, trading as Factor Therapeutics
Tel: +61 7 3334 3900
Email: c.behrenbruch@factor-therapeutics.com

About Factor Therapeutics

Tissue Therapies Limited (trading as Factor Therapeutics) is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Factor Therapeutics is commercialising VF-001 (previously denoted VitroGro® ECM), a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The business owns various patent families related to wound healing and other therapeutic uses. The Company's shares are traded on the Australian, Berlin and Frankfurt stock exchanges. For more information, please visit www.factor-therapeutics.com

Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. This document may not be distributed or released in the United States.